{"title":"$158,000 ALS drug pulled from market after failing in large clinical trial","link":"https://arstechnica.com/?p=2015321","date":1712356132000,"content":"<div>\n<figure>\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2024/04/Amylyx-Cambridge-Office-2_Source_-Amylyx-800x600.jpg\" alt=\"$158,000 ALS drug pulled from market after failing in large clinical trial\" />\n      <p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2024/04/Amylyx-Cambridge-Office-2_Source_-Amylyx-scaled.jpg\">Enlarge</a> (credit: <a href=\"https://www.amylyx.com/news\">Amlyx</a>)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>Amylyx, the maker of a new drug to treat ALS, is pulling that drug from the market and laying off 70 percent of its workers after a large clinical trial found that the drug did not help patients, <a href=\"https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior/albriozatm-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy\">according to an announcement from the company Thursday</a>.</p>\n<p>The drug, Relyvrio, won approval from the Food and Drug Administration in September 2022 to slow the progression of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease). However, the data behind the controversial decision was shaky at best; it was based on a study of just 137 patients that had <a href=\"https://www.science.org/content/blog-post/new-als-drug\">several weaknesses and questionable statistical significance</a>, and FDA advisors initially voted against approval. Still, given the severity of the neurogenerative disease and lack of effective treatments, the FDA ultimately granted approval under the condition that the company was working on a Phase III clinical trial to solidify its claimed benefits.</p>\n<p>Relyvrio—a combination of two existing, generic drugs—went on the market with a list price of <a href=\"https://www.nytimes.com/2022/09/30/health/relyvrio-price-als-amylyx.html\">$158,000</a>.</p></div><p><a href=\"https://arstechnica.com/?p=2015321#p3\">Read 4 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=2015321&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"850e70b9cdbbe9114d3ae552ec708ccb86d01b9137a25f33ac1837e70ac80bec","category":"Tech"}